Portal de Periódicos da CAPES

New options for drug treatment of obesity in patients with Type 2 diabetes

2005; Wiley; Volume: 22; Issue: s4 Linguagem: Inglês

10.1111/j.1464-5491.2005.1761h.x

1464-5491

R.L. Kennedy, Eric Yin Hao Khoo,

Diabetes Treatment and Management

Diabetic MedicineVolume 22, Issue s4 p. 23-26 New options for drug treatment of obesity in patients with Type 2 diabetes R. L. Kennedy, R. L. Kennedy Department of Medicine, James Cook University, Queensland, Australia, andSearch for more papers by this authorE. Y. H. Khoo, E. Y. H. Khoo Department of Diabetes & Endocrinology, Queen's Medical Centre, Nottingham, UKSearch for more papers by this author R. L. Kennedy, R. L. Kennedy Department of Medicine, James Cook University, Queensland, Australia, andSearch for more papers by this authorE. Y. H. Khoo, E. Y. H. Khoo Department of Diabetes & Endocrinology, Queen's Medical Centre, Nottingham, UKSearch for more papers by this author First published: 15 August 2005 https://doi.org/10.1111/j.1464-5491.2005.1761h.xCitations: 1Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142: 532– 546. 2 Torgerson Jarl S, Hauptman J, Boldrin Mark N, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155– 161. 3 Kelley David E, Kuller Lewis H, McKolanis Therese M, Harper P, Mancino J, Kalhan S. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care 2004; 27: 33– 40. 4 Arterburn David E, Crane Paul K, Veenstra David L. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004; 164: 994– 1003. 5 Kim Su H, Lee Young M, Jee Sun H, Nam Chung M. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res 2003; 11: 1116– 1123. 6 Vettor R, Serra R, Fabris R, Pagano C, Federspil G. Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies. Diabetes Care 2005; 28: 942– 949. 7 McNulty Steven J, Ur E, Williams G. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 2003; 26: 125– 131. 8 Filippatos TD, Kiortsis DN, Liberopoulos EN, Mikhailidis DP, Elisaf MS. A review of the metabolic effects of sibutramine. Curr Med Res Opin 2005; 21: 457– 468. 9 Cota D, Marsicano G, Tschöp M, Grübler Y, Flachskamm C, Schubert M et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112: 423– 431. 10 Bensaid M, Gary Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F, Soubrié P. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003; 63: 908– 914. 11 Liu YL, Connoley IP, Wilson CA, Stock MJ. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes Relat Metab Disord 2005; 29: 183– 187. 12 Osei Hyiaman D, Depetrillo M, Pacher P, Liu J, Rodaeva S, Bátkai S, et al. Endocannabinoid activation at hepatic CB(1) receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005; 115: 1298– 1305. 13 Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, Soubrié P. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet- induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003; 284: R345– R353. 14 Van Gaal Luc F, Rissanen Aila M, Scheen André J, Ziegler O, Rössner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389– 1397. 15 Klein Thomas W. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 2005; 5: 400– 411. 16 Greeno CG, Wing RR. A double-blind, placebo-controlled trial of the effect of fluoxetine on dietary intake in overweight women with and without binge-eating disorder. Am J Clin Nutr 1996; 64: 267– 273. 17 Jain AK, Kaplan RA, Gadde KM, Wadden TA, Allison DB, Brewer ER Et Al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res 2002; 10: 1049– 1056. 18 Wilkes Jason J, Nelson E, Osborne M, Demarest Keith T, Olefsky Jerrold M. Topiramate is an insulin-sensitizing compound in vivo with direct effects on adipocytes in female ZDF rats. Am J Physiol Endocrinol Metab 2005; 288: E617– E624. 19 Ortmann S, Kampe J, Gossel M, Bickel M, Geisen K, Jähne G et al. The novel antiobesic HMR1426 reduces food intake without affecting energy expenditure in rats. Obes Res 2004; 12: 1290– 1297. 20 Ahrén B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 2004; 36: 11– 12. Further reading 21 Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J. Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; 1: 1469– 493X. 22 Redmon JB, Raatz Susan K, Reck Kristell P, Swanson JE, Kwong CA, Fan Q et al. One-year outcome of a combination of weight loss therapies for subjects with type 2 diabetes: a randomized trial. Diabetes Care 2003; 26: 2505– 2511. 23 Redmon JB, Reck Kristell P, Raatz Susan K, Swanson JE, Kwong CA, Ji H et al. Two-year outcome of a combination of weight loss therapies for type 2 diabetes. Diabetes Care 2005; 28: 1311– 1315. 24 Halpern A, Mancini Marcio C. Diabesity: are weight loss medications effective? Treat Endocrinol 2005; 4: 65– 74. 25 Porter Julie A, Raebel Marsha A, Conner Douglas A, Lanty FA, Vogel EA, Gay EC, Merenich JA. The Long-term Outcomes of Sibutramine Effectiveness on Weight (LOSE Weight) study: evaluating the role of drug therapy within a weight management program in a group-model health maintenance organization. Am J Manag Care 2004; 10: 369– 376. Citing Literature Volume22, Issues4September 2005Pages 23-26 ReferencesRelatedInformation